Opinion|Videos|May 17, 2024
Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer
Author(s)Stephanie L. Graff, MD
Stephanie Graff, MD, concludes the discussion with thoughts on endocrine therapies in development for patients with ER+/HER2- metastatic breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
4
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
5